核苷类似物对乙肝相关性肝癌晚期患者生存质量的影响

目的：研究核苷类似物对乙肝相关性肝癌晚期患者生存质量的影响。方法：选取2010年4月-2013年11月期间本院收治的72例乙肝相关性肝癌晚期患者作为研究资料，将72例患者随机分为研究组和对照组，研究组患者接受核苷类似物抗病毒联合肝癌晚期常规治疗，对照组患者接受常规治疗，对照两组患者的生存质量评分。结果：两组患者治疗前各项指标无统计学差异（P〉0．05），两组患者治疗后各肝功能指标均较治疗前显著改善，研究组患者治疗后的总胆红素（TBiL）显著低于对照组（P〈0．05）。两组患者治疗前各领域及单项评分无统计学差异（P〉0．05），治疗后躯体功能、角色功能以及情绪功能均较治疗前显著改善（P〈0．05），且研究组患者治疗后的躯体功能、角色功能以及情绪功能显著高于对照组患者治疗后（P〈0．05）。结论：核苷类似物治疗乙肝相关性肝癌晚期患者可以有效提高患者的生存质量。

Effect of nucleoside analogue therapy on quality of life in HBV-related patients with ad- vanced hepatocellular carcinoma

Objective To explore the effect of hepatitis B nucleoside analogue therapy on quality of life of patients with advanced hepatocellular carcinoma. Methods： From April 2010 to November 2013, a total of 72 cases of HBV-related liver cancer were selected, and were randomly divided into study group and the control group. Patients in the study group received antiretroviral therapy in combination with nucleoside similar to the conventional treatment of advanced liver cancer, patients in the control group received conventional treatment. Quality of life score were observed. Results There was no difference in all indexes between two groups. After treatment liver function of two groups was significantly improved, TBiL of study group after treatment was significantly lower than the control group. There was no difference in score. After treatment in two groups physical function, role function and emotional function were significantly improved. And the improvement in study group was more significant after treatment. Conclusion： Nucleoside analogue therapy can effectively improve the quality of life of patients with HBV-related liver cancer.